Full-Time

Global Product Monitoring Vigilance Report Writer

Confirmed live in the last 24 hours

Insulet Corporation

Insulet Corporation

1,001-5,000 employees

Develops insulin delivery systems for diabetes

Compensation Overview

$67.3k - $100.9k/yr

Mid

Acton, MA, USA

Hybrid

Requires on-site work from an Insulet office at least three (3) days per week.

Category
Editing & Proofreading
Technical Writing
Content & Writing
Requirements
  • Bachelor’s degree or appropriate combination of relevant education and experience.
  • Minimum 3 years of demonstrated experience in medical device complaint triage and vigilance reporting or 3 years clinical experience in diabetes disease management or diabetes device support.
Responsibilities
  • Responsible for the assessment, follow-up, coding, and vigilance activities for complaints globally.
  • Author, peer review, and approve vigilance reports to ensure on time submissions to the appropriate regulatory authorities.
  • Support management in day-to-day operations in a fast-paced work environment; Support proper coding of complaints and reportable events.
  • Collaborate with engineering, complaint investigation laboratory, medical and other internal staff as applicable to review events, coding, and investigation results to support regulatory reporting compliance occurs per procedures, standards, and regulations.
  • Contribute to departmental non-conformances escalated into CAPA System
  • Serve as a subject matter expert for post-market and complaint handling regulatory questions and inquiries.
  • Support internal and external audits and inspections.
  • Assist with special projects, as assigned, with minimal supervision.
  • Perform other duties as required.
Desired Qualifications
  • Strong proficiency in common computer applications such as Microsoft Office (Excel, Word, Outlook) and complaint database applications.
  • Effective verbal and written communication skills.
  • Ability to generate, verify, and maintain accurate records.
  • Must have analytical skills, be detail oriented, and have good interpersonal skills.
  • Demonstrated ability to influence without authority.
  • Ability to organize, judge priorities, and escalate when applicable.
  • Strong emphasis and understanding of a formalized medical device Quality Management System.
  • Direct experience of 3 or more years in writing and filing global vigilance reports within the medical device industry.
  • Working knowledge/experience with global, multi-country vigilance reporting requirements for medical devices and demonstrated knowledge of country-specific differences and requirements.
  • Experience in dealing directly with regulatory bodies is highly desired.
  • BSN with diabetes experience, Registered or Licensed Dietician or Diabetic Educator, preferred.

Insulet Corporation develops and manufactures insulin delivery systems specifically for individuals with diabetes. Its main product, the Omnipod, is a tubeless and waterproof insulin pump that allows for continuous insulin infusion under the skin. This system is designed to be more convenient and discreet compared to traditional insulin pumps that use tubing, making diabetes management easier for users. Insulet operates globally, with its headquarters in Acton, Massachusetts, and various manufacturing facilities around the world. The company focuses on selling the Omnipod system, which includes disposable pods and a personal diabetes manager (PDM). Insulet targets people with insulin-dependent diabetes who prefer a flexible and user-friendly method of insulin delivery. The company is also advancing its product line with innovations like the Omnipod 5, an automated insulin delivery system that works with continuous glucose monitors.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Acton, Massachusetts

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Omnipod 5 iPhone app launch enhances user experience with Dexcom G7 compatibility.
  • Insulet's humorous campaign and Marvel collaboration boost brand visibility and engagement.
  • $450M raised through senior notes optimizes capital structure for future growth.

What critics are saying

  • CEO transition may lead to strategic shifts or instability during the transition period.
  • Increased competition from Tandem Diabetes Care could impact Insulet's market share.
  • Integration of Omnipod 5 with Dexcom G7 may face technical challenges or user adoption issues.

What makes Insulet Corporation unique

  • Omnipod is tubeless and waterproof, unlike traditional insulin pumps with tubing.
  • Omnipod 5 integrates with CGMs, offering automated insulin delivery for personalized diabetes management.
  • Insulet's global presence and innovative product line set it apart in diabetes care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Diabetic Investor
Jun 25th, 2025
ADA 2025 - Winners and losers

It goes without saying that Insulet was not just the winner of ADA 2025 it won by a landslide.

TTF Valve
Jun 12th, 2025
Insulet (NasdaqGS:PODD) Launches Omnipod 5 iPhone App With Dexcom G7 Compatibility - Simply Wall St News

Insulet (NasdaqGS:PODD) launches Omnipod 5 iPhone App with Dexcom G7 compatibility - Simply Wall St news.

MediaPost
Jun 11th, 2025
Insulet Boosts Its Diabetes Device Via Comical Campaign - And A Comic Book

Insulet has launched a humorous paid social campaign for its wearable Omnipod 5 insulin delivery system - and teamed with Marvel for a stigma-busting comic book starring a teen heroine with diabetes.

RTTNews
Apr 28th, 2025
Insulet CEO Jim Hollingshead Resigns, Ashley McEvoy To Succeed; Raises Q1 Guidance

Insulet Corp. (PODD), a medical device company, on Monday announced that Chief Executive Officer Jim Hollingshead has resigned from the Board of Directors.

MD+DI
Apr 28th, 2025
Insulet Names Ex-J&J MedTech Chief Ashley McEvoy as CEO

Ashley McEvoy has been tapped to be president and CEO of Insulet.